Chemotherapy linked to mitochondrial dysfunction in skeletal muscle

(Natural News) A study published in the American Journal of Physiology-Cell Physiology has found that chemotherapy can cause adverse effects on the skeletal muscle of patients undergoing treatment. In the study, researchers from the University of Vermont looked at whether chemotherapeutics for breast cancer impact skeletal muscle structure and protein expression. The researchers involved 13 women...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news

Related Links:

AbstractPurpose of ReviewImmune checkpoint blockade (ICB) has changed the clinical course of multiple cancer types and durable responses have now been observed in breast cancer (BC) patients. Most data suggest that, compared to other subtypes, triple-negative BC (TNBC) patients are more responsive to ICB, and anti-PD-L1 therapy is now approved in PD-L1+ metastatic TNBC, in combination with chemotherapy.Recent FindingsNearly 40% of PD-L1+ TNBC patients did not respond to this combination. Thus, additional biomarkers appear to be necessary to more precisely identify potential responders. A comprehensive analysis of the breas...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
AbstractPurpose of reviewAs the treatment of many malignancies has improved, brain metastases (BM) have been observed as a site of the first recurrence in patients with controlled systemic cancers. This suggests that while the administered chemotherapy is effective against systemic cancer, drug concentrations in the central nervous system (CNS) are likely too low to be effective. These findings are in accord with data suggesting that more than 98% of FDA-approved drugs on the market today are unable to cross the blood-brain barrier (BBB).Recent findingsThis retrospective literature review was conducted to estimate the prop...
Source: Current Treatment Options in Neurology - Category: Neurology Source Type: research
Condition:   Cancer Metastatic Interventions:   Drug: Paclitaxel injection;   Drug: Capecitabine tablets;   Drug: Letrozole 2.5mg;   Drug: Anastrozole 1mg;   Drug: Fulvestrant Prefilled Syringe;   Drug: Abemaciclib Sponsor:   UNICANCER Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   Sentinel Lymph Node Interventions:   Diagnostic Test: mapping agent;   Procedure: neoadjuvant chemotherapy Sponsor:   Xijing Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cancer Metastatic Interventions:   Drug: Paclitaxel injection;   Drug: Capecitabine tablets;   Drug: Letrozole 2.5mg;   Drug: Anastrozole 1mg;   Drug: Fulvestrant Prefilled Syringe;   Drug: Abemaciclib Sponsor:   UNICANCER Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   Sentinel Lymph Node Interventions:   Diagnostic Test: mapping agent;   Procedure: neoadjuvant chemotherapy Sponsor:   Xijing Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cancer Metastatic Interventions:   Drug: Paclitaxel injection;   Drug: Capecitabine tablets;   Drug: Letrozole 2.5mg;   Drug: Anastrozole 1mg;   Drug: Fulvestrant Prefilled Syringe;   Drug: Abemaciclib Sponsor:   UNICANCER Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   Sentinel Lymph Node Interventions:   Diagnostic Test: mapping agent;   Procedure: neoadjuvant chemotherapy Sponsor:   Xijing Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
razia Daidone Matteo Dugo Triple negative breast cancer (TNBC) patients not attaining pathological Complete Response (pCR) after neo-adjuvant chemotherapy (NAC) have poor prognosis. We characterized 19 patients for somatic mutations in primary tumor biopsy and residual disease (RD) at surgery by 409 cancer-related gene sequencing (IonAmpliSeqTM Comprehensive Cancer Panel). A median of four (range 1–66) genes was mutated in each primary tumor biopsy, and the most common mutated gene was TP53 followed by a long tail of low frequency mutations. There were no recurrent mutations significantly associated with pC...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Scientists have developed a new genetic fingerprint test which aims to identify women with breast cancer who are likely to respond to a class of often-useful, but toxic chemotherapy agents including one commonly referred to as " the red devil " by patients and survivors.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Physiology | Study | Women